Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

NCT03297879 on ClinicalTrials.gov · last registry update 2017-10-02

An unusually large phase 4: 230 participants, more than double the 75 typical for the stage. The sponsor logged completion for 28 February 2016. Primary outcome, as filed: The change of HbA1c. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Beijing Chao Yang Hospital
Sponsor type: Other
Enrollment: 230
Started: 2013-01-01
Primary completion: 2016-02-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The change of HbA1c

Conditions studied

Type2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.